Pub Date : 2024-11-19DOI: 10.1016/j.tcm.2024.10.005
Rachel L Goldberg, Sindhu Prabakaran, Nandita S Scott
Cardiovascular disease remains a major contributor to maternal morbidity and mortality in the United States. Cardio Obstetrics is a nascent field for which most cardiovascular clinicians have not received any formal training. This has resulted in knowledge and care gaps. In this review we provide principles to guide the care for the evaluation and management of pregnancy capable individuals, which should be considered the standard knowledge for all clinicians.
{"title":"Cardio Obstetrics: bridging heart and pregnancy health.","authors":"Rachel L Goldberg, Sindhu Prabakaran, Nandita S Scott","doi":"10.1016/j.tcm.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.tcm.2024.10.005","url":null,"abstract":"<p><p>Cardiovascular disease remains a major contributor to maternal morbidity and mortality in the United States. Cardio Obstetrics is a nascent field for which most cardiovascular clinicians have not received any formal training. This has resulted in knowledge and care gaps. In this review we provide principles to guide the care for the evaluation and management of pregnancy capable individuals, which should be considered the standard knowledge for all clinicians.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-19DOI: 10.1016/j.tcm.2024.11.002
Andrew S Tseng, Mayank Sardana, John R Giudicessi, Michael J Ackerman
Unexplained sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in the young remains a critical issue for clinicians, researchers, patients and their family members. In this review, we explore the current status of SCA and SCD evaluation in the young, including recent monogenic and polygenic disease discoveries, advancements in cardiac imaging and our growing understanding of the role of the Purkinje system in triggering life threatening and even fatal ventricular arrhythmias. Yet, despite these advancements, over a third of SCA and SCD among individuals with seemingly structurally normal hearts remain unexplained. We explore the future role of artificial intelligence, novel biomarkers, multimodality cardiac imaging, genetic discoveries, as well as wearable devices and sensors in closing this current gap. With the overarching framework provided in this review, we envision a future in which collaboration among patients, clinicians, researchers, innovators, and policy makers culminates in our ability to diagnose, predict, and ultimately prevent SCA and SCD in the young.
{"title":"Unexplained Sudden Cardiac Arrest and Sudden Cardiac Death in the Young: What is Killing These Young People When Nothing is Found?","authors":"Andrew S Tseng, Mayank Sardana, John R Giudicessi, Michael J Ackerman","doi":"10.1016/j.tcm.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.tcm.2024.11.002","url":null,"abstract":"<p><p>Unexplained sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in the young remains a critical issue for clinicians, researchers, patients and their family members. In this review, we explore the current status of SCA and SCD evaluation in the young, including recent monogenic and polygenic disease discoveries, advancements in cardiac imaging and our growing understanding of the role of the Purkinje system in triggering life threatening and even fatal ventricular arrhythmias. Yet, despite these advancements, over a third of SCA and SCD among individuals with seemingly structurally normal hearts remain unexplained. We explore the future role of artificial intelligence, novel biomarkers, multimodality cardiac imaging, genetic discoveries, as well as wearable devices and sensors in closing this current gap. With the overarching framework provided in this review, we envision a future in which collaboration among patients, clinicians, researchers, innovators, and policy makers culminates in our ability to diagnose, predict, and ultimately prevent SCA and SCD in the young.</p>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/j.tcm.2024.10.004
Gabriele Fragasso
{"title":"Applying guidelines directed medical therapy for heart failure: The cardiologist hard job.","authors":"Gabriele Fragasso","doi":"10.1016/j.tcm.2024.10.004","DOIUrl":"https://doi.org/10.1016/j.tcm.2024.10.004","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.tcm.2024.01.008
Brad Dieter
{"title":"Editorial commentary: Exercise and the risk of atrial fibrillation at both ends of the pathological and physiological hypertrophy spectrum","authors":"Brad Dieter","doi":"10.1016/j.tcm.2024.01.008","DOIUrl":"10.1016/j.tcm.2024.01.008","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 8","pages":"Pages 516-517"},"PeriodicalIF":7.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.tcm.2024.03.001
Nicholas Beccarino, Moussa Saleh, Laurence M. Epstein
Pacemakers have been the cornerstone of brady-arrhythmia management since the mid-20th century. Despite the widespread use and success of traditional transvenous pacemakers, they are associated with an estimated 15 % complication rate at three years. Driven by the advantages over traditional transvenous pacemakers including a lack of transvenous leads, resistance to infection, and ease of implantation, the number of leadless pacemakers placed annually in the United States has dramatically increased since their initial approval. While current iterations of leadless pacemakers lack the versatility offered by transvenous devices, recent advances in leadless pacing offer an increasingly diverse range of therapeutic options. This review will discuss the past, present, and future emerging technologies, and strategies in leadless pacing
{"title":"Leadless pacemakers: Where are we?","authors":"Nicholas Beccarino, Moussa Saleh, Laurence M. Epstein","doi":"10.1016/j.tcm.2024.03.001","DOIUrl":"10.1016/j.tcm.2024.03.001","url":null,"abstract":"<div><div>Pacemakers have been the cornerstone of brady-arrhythmia management since the mid-20th century. Despite the widespread use and success of traditional transvenous pacemakers, they are associated with an estimated 15 % complication rate at three years. Driven by the advantages over traditional transvenous pacemakers including a lack of transvenous leads, resistance to infection, and ease of implantation, the number of leadless pacemakers placed annually in the United States has dramatically increased since their initial approval. While current iterations of leadless pacemakers lack the versatility offered by transvenous devices, recent advances in leadless pacing offer an increasingly diverse range of therapeutic options. This review will discuss the past, present, and future emerging technologies, and strategies in leadless pacing</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 8","pages":"Pages 531-538"},"PeriodicalIF":7.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.tcm.2024.03.003
Kleopatra Alexiadou , Adam Hartley , Tricia M-M Tan , Ramzi Khamis
Obesity and overweight affect almost one third of the European population. Obesity and its associated conditions, including type 2 diabetes, significantly impact healthcare systems, life expectancy and quality of life. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of obesity, with or without diabetes, has provided an effective alternative to metabolic surgery and dietary interventions. We are now beginning to understand their pleiotropic effects beyond weight loss, such as their favourable impact on cardiovascular profiles. The aim of this review is to summarize available preclinical and clinical data on the beneficial effects of GLP-1 receptor agonists on atherosclerosis and cardiovascular disease which has the potential to substantially broaden the scope of their clinical applications.
{"title":"The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action","authors":"Kleopatra Alexiadou , Adam Hartley , Tricia M-M Tan , Ramzi Khamis","doi":"10.1016/j.tcm.2024.03.003","DOIUrl":"10.1016/j.tcm.2024.03.003","url":null,"abstract":"<div><div>Obesity and overweight affect almost one third of the European population. Obesity and its associated conditions, including type 2 diabetes, significantly impact healthcare systems, life expectancy and quality of life. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of obesity, with or without diabetes, has provided an effective alternative to metabolic surgery and dietary interventions. We are now beginning to understand their pleiotropic effects beyond weight loss, such as their favourable impact on cardiovascular profiles. The aim of this review is to summarize available preclinical and clinical data on the beneficial effects of GLP-1 receptor agonists on atherosclerosis and cardiovascular disease which has the potential to substantially broaden the scope of their clinical applications.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 8","pages":"Pages 552-557"},"PeriodicalIF":7.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.tcm.2024.03.006
Antoine Da Costa, Karim Benali
{"title":"Editorial commentary: Leadless pacemaker: The revolution is underway","authors":"Antoine Da Costa, Karim Benali","doi":"10.1016/j.tcm.2024.03.006","DOIUrl":"10.1016/j.tcm.2024.03.006","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 8","pages":"Pages 539-540"},"PeriodicalIF":7.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.tcm.2024.03.002
Parta Hatamizadeh
The knowledge about the pathophysiology of cardiorenal syndrome has evolved remarkably over the past two decades. However, cardiorenal syndrome is only one subject within a much broader field of nephrocardiology, which encompasses the interconnection between nephrology and cardiovascular medicine from nine different standpoints of pathophysiology, epidemiology, prevention, prognosis, diagnosis, therapy, monitoring, risk factors and systemic diseases. The complexities of these nine elements of the interaction between nephrology and cardiovascular medicine are not adequately addressed in either of those two fields of medicine. Nephrocardiology is an emerging field in medicine aiming at addressing those subtleties to improve prognosis and quality of life of a large and vulnerable patient population with combined cardiovascular and nephrology related conditions.
{"title":"From cardiorenal syndrome to nephrocardiology: The journey of exploring the interconnection between nephrology and cardiovascular medicine","authors":"Parta Hatamizadeh","doi":"10.1016/j.tcm.2024.03.002","DOIUrl":"10.1016/j.tcm.2024.03.002","url":null,"abstract":"<div><div><span><span>The knowledge about the pathophysiology of </span>cardiorenal syndrome has evolved remarkably over the past two decades. However, cardiorenal syndrome is only one subject within a much broader field of nephrocardiology, which encompasses the interconnection between </span>nephrology<span><span> and cardiovascular medicine<span> from nine different standpoints of pathophysiology, epidemiology, prevention, prognosis, diagnosis, therapy, monitoring, risk factors and </span></span>systemic diseases<span>. The complexities of these nine elements of the interaction between nephrology and cardiovascular medicine are not adequately addressed in either of those two fields of medicine. Nephrocardiology is an emerging field in medicine aiming at addressing those subtleties to improve prognosis and quality of life of a large and vulnerable patient population with combined cardiovascular and nephrology related conditions.</span></span></div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 8","pages":"Pages 541-546"},"PeriodicalIF":7.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}